Cytokines are small proteins that coordinate immune responses. During infection or tissue damage, they can recruit immune cells, alter blood-vessel behavior and regulate the production of other inflammatory molecules. Although the brain was once considered largely isolated from immune activity, research over recent decades has shown that immune signals can reach and influence the central nervous system through several routes. Cytokines can act on cells lining blood vessels, pass through regions with specialized vascular properties, signal along nerves and stimulate immune-like cells already present within the brain.

This communication system is essential for survival. When a virus or bacterium invades the body, inflammatory signals can alter sleep, appetite, body temperature and motivation, helping redirect energy toward recovery. The same signals can also modify attention, pain sensitivity and emotional behavior. These short-term changes are often adaptive, but prolonged or excessive cytokine activity may become harmful. The review describes immune-to-brain communication as a dynamic process capable of changing the operation of neural networks rather than simply switching isolated neurons on or off.

One important target is microglia, the resident immune cell population of the brain. Microglia constantly monitor the neural environment and respond to molecular signs of injury or infection. Cytokines can change their state, prompting them to release additional signaling molecules, alter their interactions with neurons and influence the removal or remodeling of synapses. Synapses are the connection points through which neurons communicate, and their strength and number determine how information flows through a circuit. If inflammatory signaling remains active, normal synaptic maintenance may be disrupted.

Cytokines can also affect astrocytes, the abundant support cells that regulate neurotransmitters, ions and energy around neurons. By changing astrocyte function, inflammation may disturb the chemical conditions required for precise neuronal signaling. At the same time, cytokines can influence the blood-brain barrier, a selective interface that controls movement between the bloodstream and brain tissue. Increased barrier permeability or altered transport activity may expose neural cells to a different immune environment, potentially amplifying inflammatory signals inside the brain.

The consequences may be particularly significant in neural circuits responsible for mood, cognition, reward, movement and sensory processing. Inflammatory mediators can influence neurotransmitter systems such as glutamate, gamma-aminobutyric acid, dopamine and serotonin, each of which contributes to communication between neuronal populations. Cytokine signaling may also affect ion channels, intracellular pathways and the expression of genes that control neuronal excitability. These effects provide a biological explanation for why systemic inflammation can be accompanied by fatigue, concentration problems, mood changes or altered pain responses.

The review also highlights the importance of timing and location. A brief cytokine response may produce temporary changes that disappear once the immune threat is resolved. By contrast, chronic inflammation, repeated immune activation or an impaired ability to shut down inflammatory pathways may lead to persistent circuit remodeling. During development and aging, when neural networks are undergoing major changes, immune signals may have especially pronounced effects. The outcome is likely to depend on the cytokine involved, the cells receiving the signal, the brain region affected and the existing condition of the neural circuit.

These mechanisms are relevant to a broad range of neurological and psychiatric conditions in which inflammation and circuit dysfunction appear to intersect. They may help explain why immune activation is associated with cognitive decline, depressive symptoms, chronic pain, seizures and other disorders. However, the relationship is not simple: cytokines can be protective in one context and damaging in another. Blocking inflammation indiscriminately could interfere with tissue repair or antimicrobial defense, making it important to distinguish harmful signaling from the immune activity required for normal protection.

By bringing together evidence from immunology, neuroscience and molecular biology, Lee, Ko and Um present immune-to-brain signaling as a potential framework for understanding neural circuit disorders. The review points toward therapeutic strategies that target specific cytokines, receptors, cellular responses or communication routes rather than suppressing the entire immune system. Future research will need to determine which inflammatory signals drive particular circuit abnormalities, how these changes can be measured in patients and whether restoring immune balance can improve brain function. The central message is increasingly clear: the brain does not operate apart from the immune system, and the molecular conversation between them may be one of the keys to understanding—and eventually treating—disorders of neural circuitry.

Subject of Research: Cytokine-mediated immune-to-brain signaling and its role in neural circuit disorders

Article Title: Cytokine-mediated immune-to-brain signaling in neural circuit disorders

Article References: Lee, Y., Ko, J. & Um, J.W. Cytokine-mediated immune-to-brain signaling in neural circuit disorders. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01796-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01796-y

Keywords: Cytokines, neuroinflammation, immune-to-brain signaling, neural circuits, microglia, astrocytes, blood-brain barrier, synaptic dysfunction, neurological disorders, psychiatric disorders

Neuroinflammation is characterized by the activation of glial cells, particularly microglia, the resident immune cells of the brain. Microglial activation is a hallmark of various neurological disorders. When neurons become damaged or stressed, microglia respond by engulfing debris and secreting pro-inflammatory cytokines. The role of TREM2 in this context is multifaceted, involving the regulation of microglial activation, cell survival, and even the clearance of amyloid-beta plaques, which are notorious for their involvement in Alzheimer’s disease pathology.

Research has shown that mutations in the TREM2 gene are associated with an increased risk of developing Alzheimer’s disease. This correlation underscores the importance of TREM2’s functions in neuroinflammatory responses throughout the disease’s progression. Such mutations appear to impair the TREM2 signaling pathway, leading to inadequate microglial responses to neuronal damage. Consequently, understanding how TREM2 integrates signals in the neuroinflammatory landscape is crucial for devising targeted therapies that can enhance its function or mimic its activity.

Recent advances in our understanding of TREM2 have revealed complex signaling mechanisms governing its activity. The binding of ligands to TREM2 activates intracellular signaling pathways that can enhance microglial survival and promote tissue repair. Additionally, TREM2 signaling is linked to phagocytosis, a process wherein microglia engulf and digest cellular debris and harmful pathogens. This phagocytic activity is vital for maintaining homeostasis in the central nervous system and preventing excessive inflammation.

Interestingly, TREM2’s role extends beyond microglial function. Emerging studies suggest that it may influence the behavior of other immune cells within the brain, such as astrocytes and macrophages. The dialogue between these cell types and TREM2-expressing microglia offers a more comprehensive understanding of neuroinflammatory mechanisms and their contributions to neurodegenerative diseases.

In the quest for therapeutic translation, TREM2 has emerged as a viable drug target. Strategies that enhance TREM2’s activity or mimic its effects have the potential to protect neurons from apoptosis and foster a more robust immunological defense against neurodegeneration. For instance, pharmacological agents that amplify TREM2 signaling are being explored in preclinical models, with the hope of transitioning these findings into clinical applications.

Notably, the therapeutic potential of TREM2 extends beyond Alzheimer’s disease. Researchers are investigating its role in other neurological disorders characterized by neuroinflammatory processes, such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), and traumatic brain injury. Each of these conditions presents unique challenges and opportunities for TREM2-targeted interventions, highlighting the need for tailored therapeutic approaches based on the underlying pathology.

In summary, the role of TREM2 in neuroinflammation is a burgeoning field of study with substantial implications for clinical outcomes. As researchers delve deeper into the molecular pathways associated with TREM2, the hope is that a clearer picture will emerge regarding its multifaceted role in neurodegenerative diseases. This could signal a paradigm shift in how these diseases are understood and managed in the future, potentially leading to more effective treatments that address not just the symptoms but the underlying pathophysiology.

Scientific collaboration will be essential in this endeavor, bringing together expertise from immunology, neurology, and pharmacology. As more discoveries are made, the translation of these findings into clinical practice will depend on rigorous testing and validation in human populations. Thus, while significant strides have been made in understanding TREM2, the path to therapeutic application requires ongoing research, experimentation, and commitment from the scientific community.

An intriguing facet of TREM2 research is the exploration of biomarker potential. With TREM2’s associations with neurodegenerative diseases, measuring TREM2 levels in biological fluids could provide valuable diagnostic information. Such biomarkers could help in early detection and offer insights into disease progression, thereby enhancing patient management strategies.

The road ahead promises exciting developments as scientists continue to unravel the intricacies of neuroinflammation and the role of TREM2 within it. The intricate balance between inflammation and neuroprotection governed by TREM2 represents a critical frontier in biomedical research. Future studies will likely aim at discovering how to harness TREM2’s protective capabilities to foster brain health and mitigate the effects of neurodegenerative diseases.

By understanding TREM2’s mechanisms and exploring its therapeutic potential, the goal remains clear: to translate these insights into tangible benefits for individuals afflicted by neurodegenerative disorders. The interplay of neuroinflammation and neurodegeneration is vast and complex, but TREM2 stands out as a beacon of hope in the fight against these debilitating diseases.

As research marches forward, it is crucial for the scientific community to remain vigilant and collaborative, ensuring that the knowledge gleaned from studies is swiftly applied to improve patient outcomes. The convergence of knowledge across diverse fields will be key in mitigating the extent of neuroinflammatory responses and fostering neuroprotection, potentially changing the landscape of treatment for neurodegenerative diseases.

In conclusion, the advances made in understanding TREM2 reveal not only its significance in regulating neuroinflammation but also the vast potential for developing novel therapeutic strategies aimed at enhancing brain health. As we move toward a future with better insights and interventions, TREM2 could prove to be a cornerstone in rebooting the immune landscape of the central nervous system, offering new avenues for hope to countless individuals facing the daunting challenges of neurodegenerative diseases.

Subject of Research: Role of TREM2 in neuroinflammation regulation and its therapeutic potential.

Article Title: Role of TREM2 in neuroinflammation regulation: mechanisms, disease associations, and therapeutic translation advances.

Article References:

Liao, Y., Mu, G., Deng, S. et al. Role of TREM2 in neuroinflammation regulation: mechanisms, disease associations, and therapeutic translation advances.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07604-x

Image Credits: AI Generated

DOI:

Keywords: TREM2, neuroinflammation, neurodegenerative diseases, Alzheimer’s disease, immune response, therapeutic strategies.

At the core of this paradigm lies microglia, whose functions extend far beyond immune surveillance. During brain development, the metabolic pathways within microglia and neurons coordinate to orchestrate synaptic pruning, neuronal growth, and network refinement. The metabolic crosstalk ensures that microglia can respond appropriately to neuronal signals, modulating energy utilization to support neurogenesis and synaptic plasticity. This fine-tuned metabolic symbiosis crucially influences the establishment of functional neural circuits foundational for cognition.

In adult brains, this microglia-neuron metabolic axis continues to play a pivotal role, sustaining cognition by regulating neuroinflammation and neuronal energy demands. Microglia adapt their metabolic states dynamically, switching between glycolysis and oxidative phosphorylation depending on the neural environment and the organism’s systemic metabolic status. Such plasticity guarantees that the brain can maintain homeostasis and adapt to fluctuating physiological conditions without compromising cognitive integrity.

However, the story takes a darker turn with ageing. Here, the tightly regulated metabolic communication between microglia and neurons deteriorates, leading to increased neuroinflammatory signaling and impaired energy metabolism. Age-associated mitochondrial dysfunction in microglia fosters a pro-inflammatory phenotype that disrupts neuronal metabolic support. Consequently, cognitive decline ensues, highlighting cellular metabolism as a cornerstone of neurodegeneration pathways. These findings suggest that metabolic dysregulation within the neuroimmune milieu is a key culprit behind the cognitive deficits observed in elderly populations.

Moreover, metabolic disorders such as diabetes mellitus further exacerbate this dysfunction. Hyperglycemia-induced oxidative stress and systemic inflammation reverberate in the brain’s microenvironment, perturbing microglial metabolism and neuronal energy homeostasis. These alterations create a vicious cycle, amplifying neuroinflammatory responses and impairing synaptic function. The mechanistic insights confirm that peripheral metabolic health is intricately linked to central nervous system functionality, emphasizing the need for integrated therapeutic strategies.

Neuroinflammatory diseases illustrate another facet of this metabolic interdependence. Conditions like multiple sclerosis and Alzheimer’s disease exhibit characteristic metabolic shifts within microglia, including altered lipid metabolism and impaired autophagy. Such changes not only influence microglial activation states but also directly compromise neuronal survival and synaptic integrity. Targeting these metabolic checkpoints holds promise for modulating disease progression by restoring immunometabolic balance.

Importantly, microglial metabolic pathways are finely tuned during brain development stages, involving key regulatory molecules such as mTOR and AMPK. These molecules act as metabolic sensors and orchestrators, integrating environmental cues and energy status to calibrate microglial functions. The downstream effects impact neurotrophic support and synaptic remodeling—processes integral to cognitive maturation and plasticity. Dissecting these pathways at a molecular level opens avenues for therapeutic modulation during critical developmental windows.

In parallel, neuronal metabolism itself undergoes modulation by microglial biochemical outputs. The release of metabolites and cytokines from microglia can enhance or suppress neuronal mitochondrial function, influencing the efficiency of ATP production required for neurotransmission and plasticity. This mutual metabolic regulation cements the concept of microglia not merely as immune sentinels but as metabolic partners essential for cognitive health.

Emerging technologies such as single-cell metabolomics and high-resolution imaging have been instrumental in unraveling these complex metabolic exchanges. These methodologies enable the visualization and quantification of metabolic fluxes and signaling molecules in situ, providing unprecedented resolution into microglia-neuron interactions. As a result, researchers can now chart temporal and spatial metabolic landscapes, correlating them directly with cognitive outcomes.

On the therapeutic front, metabolic interventions targeting microglial function are gaining increasing attention. Agents that modulate microglial metabolism, such as those activating mitochondrial biogenesis or promoting anti-inflammatory metabolic states, show potential in preclinical models to enhance cognitive resilience. Such strategies herald a new era in neurotherapeutics, moving beyond symptom management to precise metabolic reprogramming.

Furthermore, lifestyle factors influencing systemic metabolism, including diet and exercise, indirectly affect microglial metabolic states and neuronal function. Nutritional compounds with antioxidant and anti-inflammatory properties can recalibrate neuroimmune metabolism, underscoring the holistic nature of brain health management. This integrative perspective advocates for multifaceted approaches combining lifestyle modification with targeted pharmacological interventions.

Critically, understanding the bidirectional metabolic dialogue also offers insights into brain plasticity under stress and injury. During neuroinflammation or after trauma, microglial metabolic reprogramming dictates the balance between neuroprotection and neurotoxicity. Fine-tuning this balance could enhance recovery processes and mitigate long-term cognitive impairments.

The dynamic neuroimmune-metabolic interface also extends implications for cognitive disorders beyond classical neurodegeneration, including psychiatric illnesses where neuroinflammation and metabolic abnormalities coexist. Investigating microglia-neuron metabolic axes could unravel new pathological mechanisms and therapeutic targets in these domains.

As the field advances, it becomes clear that the metabolic engine driving cognition is not solely neuronal but is a collaborative output of neuron and microglia interaction. This recognition shifts paradigms, highlighting that maintaining metabolic harmony within this cellular duet is vital for sustaining cognitive function through life’s span and disease.

This comprehensive mechanistic understanding sets the stage for innovative research, inspiring the design of novel biomarkers and therapies aimed at fortifying the neuroimmune metabolic nexus. The convergence of immunology, metabolism, and neuroscience stands poised to revolutionize our approach to cognitive health, with far-reaching implications for ageing societies worldwide.

In conclusion, deciphering the intricacies of microglia-neuron metabolic interactions represents a frontier in neuroscience, offering hope for ameliorating cognitive impairment across a spectrum of disorders. By targeting the metabolic determinants of brain resilience, science moves closer to unlocking the full potential of cognitive longevity in both health and disease.

Subject of Research: Interactions between microglia and neurons focusing on metabolic pathways influencing cognition in health, ageing, and neurological diseases.

Article Title: The metabolic engine of cognition: microglia–neuron interactions in health, ageing and disease.

Article References:
Asimakidou, E., Pluchino, S., Silva, B.A. et al. The metabolic engine of cognition: microglia–neuron interactions in health, ageing and disease. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01409-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01409-4

Alzheimer’s disease is characterized by an insidious cascade of pathological events, including the buildup of Aβ plaques and neurofibrillary tangles. Although the involvement of microglia—the brain’s resident immune cells—and astrocytes—the star-shaped glial cells fundamental to neuronal support—has been recognized, the precise nature of their interactions remained elusive. This study provides critical insights into how microglia dynamically regulate astrocyte states in an Aβ-dependent manner, influencing disease progression.

Central to the research is the concept that microglia act not just as independent effectors of neuroinflammation but as regulators of astrocyte behavior, thereby orchestrating a broader glial response to Aβ pathology. The authors utilized a combination of advanced single-cell transcriptomics, in vivo imaging, and functional assays in both mouse models of AD and human brain tissue to dissect the molecular cross-talk between these two glial populations.

Detailed transcriptomic analyses revealed that microglia undergo Aβ-dependent activation states characterized by a distinct gene expression profile. These reactive microglia release a suite of signaling molecules, including cytokines and chemokines, which in turn modulate astrocyte phenotypes. Notably, astrocytes exposed to microglial signals exhibited a shift toward a reactive phenotype characterized by altered calcium signaling, changes in neurotransmitter uptake mechanisms, and a pro-inflammatory secretory profile.

One of the seminal findings of this study is the identification of specific molecular pathways through which microglia influence astrocyte reactivity. The research highlights key receptor-ligand interactions, including those involving TREM2 and complement system components, which mediate the bidirectional communication between these glial cells. This microglia-driven modulation appears to amplify astrocyte response to amyloid plaques, potentially exacerbating synaptic dysfunction and neuronal damage.

These findings challenge the traditionally neuron-centric view of Alzheimer’s disease and emphasize the critical role of glial networks in shaping disease outcomes. By revealing that microglial activity directly sculpts astrocyte behavior, this study underscores the importance of targeting glial communication pathways rather than discrete cellular targets in isolation. Such an approach could yield more effective interventions capable of modulating the neuroinflammatory environment and slowing neurodegeneration.

Furthermore, the authors demonstrate that disrupting the dialog between microglia and astrocytes alters disease trajectory in mouse models. Genetic or pharmacological inhibition of microglial signaling molecules attenuated astrocyte reactivity and mitigated synaptic loss, suggesting that manipulation of this intercellular communication axis can confer neuroprotection. These preclinical findings herald promising translational opportunities for AD therapies.

Importantly, the study also validates these mechanisms in postmortem human AD brain tissue, confirming that the interplay between microglia and astrocytes observed in murine models is conserved in humans. This cross-species confirmation bolsters the relevance of microglia-astrocyte interactions in the human condition and strengthens the translational potential of targeting this pathway clinically.

The research methodology itself reflects a tour de force in modern neuroscience. The combination of single-cell RNA sequencing with sophisticated in vivo imaging allowed the investigators to map the temporal evolution of glial states during disease progression with unprecedented resolution. This approach sheds light on how microglial activation predates and potentially drives astrocytic transformation, framing a chronological sequence of glial dysfunction in Alzheimer’s disease.

This study not only advances our understanding of cellular interplay in AD but also redefines potential biomarkers for disease staging and prognosis. Reactive astrocyte signatures modulated by microglial input may serve as indicators of disease severity or progression, providing new tools for clinical assessment and therapeutic monitoring.

Moreover, the findings suggest that therapeutic strategies modulating microglial activation must carefully balance immune functions. Microglia play essential roles in debris clearance and synaptic pruning; thus, complete suppression risks detrimental side effects. Targeting the mechanisms underlying pathological microglia–astrocyte interactions while preserving physiological functions represents a delicate but crucial therapeutic frontier.

In light of these results, pharmaceutical development efforts could focus on small molecules or biologics that selectively modulate TREM2 signaling or complement pathway activity in microglia to recalibrate astrocyte reactivity. Such precision interventions might mitigate neuroinflammation without broadly suppressing immune surveillance in the central nervous system.

This study exemplifies the evolving paradigm in neurodegenerative disease research, emphasizing the brain’s cellular ecosystem rather than isolated cell types. The intimate, context-dependent communications between microglia and astrocytes unveiled here suggest that neurodegeneration emerges from complex glial networks that can be strategically targeted to restore homeostasis.

As Alzheimer’s disease continues to impose an immense societal burden, discoveries like these offer a beacon of hope by revealing novel cellular targets and mechanisms. Understanding the interplay between glial cells enhances our conceptual framework and opens avenues for innovative treatments aimed at halting or even reversing disease progression.

In conclusion, the work by Ferrari-Souza and colleagues constitutes a paradigm-shifting contribution to Alzheimer’s disease biology. By decoding the molecular dialogue between microglia and astrocytes in the context of Aβ pathology, the study illuminates the dynamic glial landscape driving neuroinflammation and neurodegeneration. Future research building on these findings may transform how the scientific community approaches Alzheimer’s therapeutics, prioritizing nuanced modulation of glial interactions to improve patient outcomes.

Subject of Research: Microglial modulation of amyloid-beta-dependent astrocyte reactivity in Alzheimer’s disease

Article Title: Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease

Article References:
Ferrari-Souza, J.P., Povala, G., Rahmouni, N. et al. Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02103-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-025-02103-0